Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

P Pal, P Zhang, SK Poddar, G Zheng - Expert opinion on …, 2022 - Taylor & Francis
Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …
被引用次数：11 相关文章
[HTML] nih.gov

[HTML][HTML] Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

P Pal, P Zhang, SK Poddar, G Zheng - Expert opinion on …, 2022 - ncbi.nlm.nih.gov
Introduction: The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.

P Pal, P Zhang, SK Poddar, G Zheng - Expert Opinion on …, 2022 - europepmc.org
Introduction: The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

P Pal, P Zhang, SK Poddar… - Expert opinion on …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …